Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
Abstract: The aim of this study was to explore the effects of dabigatran and rivaroxaban on the activities of various coagulation factors. To achieve that, 60 rabbits were randomly divided into experimental groups that received different doses of dabigatran or rivaroxaban. The effects of dabigatran and rivaroxaban on the activities of FII, FV, FVIII, FX, and activated protein C (APC) were analyzed. In the dabigatran groups, activated partial thromboplastin time and thromboplastin time (TT) were prolonged after drug administration, and the activities of FII, FV, FVIII, and FX were inhibited as the drug concentration increased. Low doses of dabigatran inhibited APC activity. In the rivaroxaban groups, APTT and TT were not significantly prolonged after drug administration. In contrast, the high-dose rivaroxaban group exhibited prolonged PT, and the degree of inhibition of the activities of FII, FV, FVIII, and FX increased as the drug concentration increased. Rivaroxaban had no significant effect on APC activity regardless of dosage. As the drug concentration increased, both NOACs had more significant inhibitory effects on the activities of FII, FV, FVIII, and FX. Low concentrations of dabigatran generated an inhibitory effect on APC activity, while high concentrations of dabigatran had no significant effect. Rivaroxaban had no significant effect on APC activity.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits ; volume:17 ; number:1 ; year:2022 ; pages:1-9 ; extent:9
Open life sciences ; 17, Heft 1 (2022), 1-9 (gesamt 9)
- Creator
-
Yin, Lu
Qi, Yuan
Ge, Zhiru
Li, Jiajin
- DOI
-
10.1515/biol-2022-0002
- URN
-
urn:nbn:de:101:1-2022071614110103752909
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yin, Lu
- Qi, Yuan
- Ge, Zhiru
- Li, Jiajin
Other Objects (12)
Patient compliance with new oral anticoagulants after major orthopaedic surgery: rivaroxaban and dabigatran compared with subcutaneous injection of fondaparinux
Der Einfluss von Dabigatran und Rivaroxaban auf die Thrombozytenfunktion
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
Innovative Antithrombotika : Ticagrelor, Prasugrel, Elinogrel, Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Vorapaxar, Atopaxar
Antikoagulation bei Vorhofflimmern – Dabigatran, Rivaroxaban oder Apixaban – die Qual der Wahl?
Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation
UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays
Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists
Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran
Dabigatran, Rivaroxaban, Apixaban, Argatroban und Fondaparinux und ihre Effekte auf Point-of-Care- sowie Plättchenfunktionstests
Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis
Patient compliance with new oral anticoagulants after major orthopaedic surgery: rivaroxaban and dabigatran compared with subcutaneous injection of fondaparinux
Der Einfluss von Dabigatran und Rivaroxaban auf die Thrombozytenfunktion
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
Innovative Antithrombotika : Ticagrelor, Prasugrel, Elinogrel, Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Vorapaxar, Atopaxar
Antikoagulation bei Vorhofflimmern – Dabigatran, Rivaroxaban oder Apixaban – die Qual der Wahl?
Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation
UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays
Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists
Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran
Dabigatran, Rivaroxaban, Apixaban, Argatroban und Fondaparinux und ihre Effekte auf Point-of-Care- sowie Plättchenfunktionstests
Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis
Patient compliance with new oral anticoagulants after major orthopaedic surgery: rivaroxaban and dabigatran compared with subcutaneous injection of fondaparinux
Der Einfluss von Dabigatran und Rivaroxaban auf die Thrombozytenfunktion
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
Innovative Antithrombotika : Ticagrelor, Prasugrel, Elinogrel, Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Vorapaxar, Atopaxar
Antikoagulation bei Vorhofflimmern – Dabigatran, Rivaroxaban oder Apixaban – die Qual der Wahl?
Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation
UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays
Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists
Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran
Dabigatran, Rivaroxaban, Apixaban, Argatroban und Fondaparinux und ihre Effekte auf Point-of-Care- sowie Plättchenfunktionstests
Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography